CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Suvorexant +1 moredrug
Likely dose
Suvorexant 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05593653
NCT05593653Phase 4Completed
CompareCT.gov

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

Brigham and Women's Hospital·interventional·Posted Oct 25, 2022·Updated Apr 16, 2026

In Brief

A Phase 4 clinical trial evaluating Suvorexant and Placebo for Insomnia and 2 related conditions. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The aim of this study is to determine if suvorexant can help treat the severity of insomnia and improve metabolic health in midlife women who had both insomnia and indicators of metabolic syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia, Metabolic Health, Menopause
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedOct 25, 2022
Enrollment StartJan 6, 2023
Primary CompletionOct 24, 2025
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 3.7 years ago

Interventions

Suvorexantdrug

20mg taken at bedtime for 4 weeks

Placebodrug

placebo taken at bedtime for 4 weeks